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Samir G MallatAbstract
Circulatory and tissue renin-angiotensin systems (RAS) play a central role in cardiovascular (CV) and renal
pathophysiology, making RAS inhibition a logical therapeutic approach in the prevention of CV and renal disease in
patients with hypertension. The cardio- and renoprotective effects observed with angiotensin-converting enzyme
(ACE) inhibitors or angiotensin II receptor blockers (ARBs) monotherapy, together with the availability of a direct
renin inhibitor (DRI), led to the investigation of the potential benefits of dual RAS inhibition. In small studies, ARB
and ACE inhibitor combinations were shown to be beneficial in patients with CV or renal disease, with
improvement in surrogate markers. However, in larger outcome trials, involving combinations of ACE inhibitors,
ARBs or DRIs, dual RAS inhibition did not show reduction in mortality in patients with diabetes, heart failure,
coronary heart disease or after myocardial infarction, and was in fact, associated with increased harm. A recent
meta-analysis of all major trials conducted over the past 22 years involving dual RAS inhibition has clearly shown
that the risk-benefit ratio argues against the use of dual RAS inhibition. Hence, the recent evidence clearly
advocates against the use of dual RAS inhibition, and single RAS inhibition appears to be the most suitable
approach to controlling blood pressure and improving patient outcomes.
Keywords: Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers, Blood pressure,
Cardiovascular disease, Dual renin-angiotensin system inhibition, Direct renin inhibitors, Outcomes, Renal diseaseIntroduction
The central role of the renin-angiotensin system (RAS) in
the regulation of blood pressure (BP) has been recognized
for many years. The discovery of tissue-based angiotensin
II production has resulted in the concept of a local RAS
that is independent of the circulating RAS.
RAS activation following the release of renin by the
kidney results in a cascade of physiological events (Figure 1).
Renin catalyzes the formation of angiotensin I, which is
then converted to angiotensin II by angiotensin-converting
enzyme (ACE), resulting in activation of the angiotensin II
receptors and its deleterious effect on renal vasculature,
resulting in chronic kidney disease (CKD) [1-6]. The
progressive development of cardiovascular (CV) disease
(CVD) resulting from pathophysiological changes mediated
by angiotensin II in the presence of risk factors is wellCorrespondence: sm104@aub.edu.lb
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reproduction in any medium, provided the orestablished [2] and local activation of RAS in the vascular
walls is thought to contribute to atherosclerosis [5].
Furthermore, intrarenal RAS is often inappropriately
activated in diabetes and is thought to predispose these
patients to nephropathy [7,8]. RAS inhibition (both
circulatory and intrarenal) is therefore a key therapeutic
approach to slow progression of CKD and to reduce
CV risk through both BP-dependent and independent
mechanisms.
All three classes of available RAS inhibitors (ACE
inhibitors, angiotensin receptor blockers [ARBs] and direct
renin inhibitors [DRIs]) interrupt the normal angiotensin II
feedback suppression of renin secretion from the kidneys
[10]. In the past two decades, landmark trials have shown
that early aggressive lowering of BP and inhibition of
the RAS improves outcomes for patients with renal
disease or CVD [11-15]. ACE inhibitors and ARBs reduce
proteinuria, slow progression of CKD and lower morbidity
and mortality rates in patients at high CVD risk, and inis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic representation of the RAS. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; AT1,
angiotensin II type 1 receptor; AT2, angiotensin II type 2 receptor; DRI, direct renin inhibitor; NO, nitric oxide; PRA, plasma renin activity;
PRC, plasma renin concentration; RAS, renin-angiotensin system; SNS, sympathetic nervous system; tPA, tissue plasminogen activator.
Adapted from Farsang 2011 [9].
Mallat Cardiovascular Diabetology 2013, 12:108 Page 2 of 12
http://www.cardiab.com/content/12/1/108patients already displaying evidence of target organ damage
(TOD) such as myocardial infarction (MI), heart failure
(HF), stable coronary heart disease (CHD) with or without
left ventricular dysfunction (LVD), and reduce mortality
and reinfarction rates in patients with LVD or HF after MI
[12-32]. Evidence from large outcome trials such as the
ONgoing Telmisartan Alone and in combination with
Ramipril Global Endpoint Trial (ONTARGET®) suggests
that ARBs like telmisartan have additional CV benefits
beyond BP lowering [33]. Outcomes with ARB monother-
apy in post-MI patients are similar to those achieved with
high doses of an ACE inhibitor [28,34]. ACE inhibitors
and ARBs are widely acknowledged to confer additional
renoprotective benefits beyond the effects of BP control
alone [35] (Table 1). ARBs are also known to activate per-
oxisome proliferator-activated receptor gamma (PPAR-γ),
however, only telmisartan exhibits increased PPAR-γ
activity at therapeutic dosages [36,37]. PPAR-γ enhances
insulin sensitivity, has positive effects on lipid metabolism,
endothelium, oxidative stress and vascular inflammation,
and its anti-inflammatory, antiatherogenic and antihyper-
tensive effects are considered to exert CV protective effects
[38,39]. Initial data suggest that, as with ARBs and ACE
inhibitors, aliskiren, an oral DRI, may protect against
TOD [40-42].
Dual RAS inhibition was theorized to result in better
RAS inhibition, giving rise to greater benefit on BP lower-
ing and cardiorenal outcomes. Early studies on dual RAS
inhibition with ACE inhibitors and ARBs have shown
greater reduction in BP with the combination [51], but
benefits on surrogate endpoints and outcomes have notbeen consistent [22,28,52-61]. The ONTARGET® study,
the largest trial of dual RAS inhibition in high-risk patients
(those with CVD or diabetes but not HF), in which patients
were randomized to receive either telmisartan or ramipril,
or a combination of the two agents, found no evidence to
support the use of dual RAS inhibition in these patients
[33,62]. This article reviews the recent evidence, including
those from large outcome trials (Table 2), for the efficacy of
dual RAS inhibition in patients at a high risk of CVD with
multiple co-morbidities such as LVD, HF, CKD and TOD.
Study selection
The PubMed database was systematically searched for
English language articles published during the period
May 2008 to May 2013, reporting results of trials com-
paring dual blockers of the RAS with monotherapy. The
search terms used were “angiotensin-converting enzyme
inhibitor”, “angiotensin receptor blocker”, “cardiovascular
disease”, “chronic kidney disease”, “diabetes”, “direct renin
inhibitor”, “dual RAS blockade”, “heart failure”, “myocardial
infarction”. The reference lists of the articles retrieved by
the electronic search also were searched for other poten-
tially eligible articles. This review also was supplemented
with publications of landmark studies on single RAS
inhibition that fell outside the search criteria.
High-risk patients with LVD or HF
A series of landmark trials with ACE inhibitors in patients
with LVD or HF such as VALsartan in Acute myocardial
INfarction (VALIANT), Valsartan in Heart Failure Trial
(Val-HeFT) and others have reported reductions in CV
Table 1 Renoprotective effects of ACE inhibitors and ARBs (large [n ~ or > 100] randomized controlled studies)
Study population Treatment arms Main findings: statistically significant renoprotective
effect of ACE inhibitor/ARB versus comparator
ACE inhibitor
IDDM patients with macroalbuminuria [17] Captopril or placebo 48% RR in doubling of serum creatinine; 50% RR of the combined
endpoint (death, dialysis and transplantation)
T2DM patients with albuminuria [43] Enalapril or placebo 1% versus 13% decline in kidney function
Nondiabetic patients with proteinuria [44] Ramipril or placebo Lower decline in GFR (0.53 ml/min versus 0.88 ml/min); RR in
doubling of baseline creatinine or ESRD
T2DM patients [45] Ramipril or placebo 24% risk reduction in overt nephropathy
T2DM patients [46] Enalapril or nifedipine Greater reduction in albuminuria; 23.8% patients (versus 15.4%)
reverted to normoalbuminuria; 19.1% patients (versus 30.8%)
developed macroalbuminuria
ARB
T2DM patients with nephropathy [13] Losartan or placebo 16% RR in doubling of serum creatinine concentration; 28% RR
in ESRD; significant reduction in proteinuria versus placebo
Hypertensive T2DM with nephropathy [11] Irbesartan or amlodipine or placebo RR of doubling serum creatinine and of ESRD
T2DM patients with nephropathy [15] Irbesartan or placebo Reduction in the onset of diabetic nephropathy compared
with placebo
T2DM patients [47] Telmisartan or placebo RR in progression to overt nephropathy; reduced UACR;
increased microalbuminuria remission
T2DM patients with hypertension [48] Telmisartan or ramipril Both telmisartan and ramipril increase NO activity of renal
endothelium which may preserve renal function
CVD and T2DM patients [49] Telmisartan or placebo Prevented increase in albuminuria (32% increase versus 63%
increase); however, telmisartan was associated with a greater
doubling of serum creatinine and decrease in estimated GFR,
although there was no difference in terms of renal outcome
T2DM patients [50] Valsartan or amlodipine Greater reduction in urine albumin excretion (44% versus 8%)
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CVD, cardiovascular disease; ESRD, end-stage renal disease; GFR, glomerular filtration
rate; IDDM, insulin-dependent diabetes mellitus; NO, nitric oxide; RR, risk reduction; T2DM, Type 2 diabetes mellitus; UACR, urinary albumin-creatinine ratio.
Mallat Cardiovascular Diabetology 2013, 12:108 Page 3 of 12
http://www.cardiab.com/content/12/1/108mortality and morbidity [22,23,25,27,28,31,32]. Evidence
for efficacy of ARB monotherapy in this patient group is
provided by the Evaluation of Losartan In The Elderly
(ELITE) I and II studies [29,30], Candesartan in Heart
failure Assessment of Reduction in mortality and Mor-
bidity (CHARM) [53,54,58,59], ONTARGET® [33] and
Telmisartan Randomized AssessmeNt Study in ACE-I
iNtolerant subjects with cardiovascular Disease (TRAN-
SCEND®) [70].
There is limited, but conflicting, evidence on the effects
of dual RAS inhibition on mortality in patients with LVD or
HF. The prevalence of left ventricular hypertrophy (LVH)
was reduced by dual RAS inhibition in ONTARGET®
(odds ratio, 0.93; 95% confidence interval (CI), 0.84 to
1.02; p = 0.12 compared with ramipril). In a pilot study
in 24 treatment-naive hypertensive patients with left
ventricular (LV) concentric hypertrophy randomized to
ramipril plus candesartan or ramipril plus lercanidipine,
the decrease of LV mass and the improvement of diastolic
function were significantly greater with ramipril plus
candesartan, suggesting a greater antiremodelling effect
[71]. A benefit of dual RAS inhibition, of telmisartan and
ACE inhibitors was apparent in a small study (n = 332) in
patients with end-stage renal disease (ESRD) in additionto HF and impaired left ventricular ejection fraction
(LVEF). The dual therapy significantly improved the three
primary outcomes of all-cause mortality (35.1% versus
54.4%; p < 0.001), CV mortality (30.3% versus 43.7%;
p < 0.001) and hospital admission for chronic HF (33.9%
versus 55.1%; p < 0.0001) compared with placebo [72].
In post-acute MI / percutaneous coronary intervention
Japanese patients, treatment with half-dose combination
of valsartan and trandolapril was observed to suppress LV
remodelling more effectively than trandolapril alone [73].
The ALiskiren Left ventricular Assessment of hypertrophY
(ALLAY) trial randomized 465 hypertensive overweight
patients with LVH to aliskiren 300 mg, losartan 100 mg
or the combination for 9 months. The combination of
aliskiren plus losartan was not significantly different
from losartan for the primary outcome of reduction in
LV mass [65]. In a subset of 136 patients who had plasma
aldosterone concentration measured at baseline and study
end, aliskiren, either alone or in combination, resulted in a
significantly greater reduction from baseline to 9 months
in plasma aldosterone than losartan alone, and the
suppression of aldosterone was associated with reduction
of LVH, independently of the change in systolic blood
pressure (SBP) [74].
Table 2 Overview of large outcome trials investigating dual RAS inhibition
Study name or author Study population ACE inhibitor ARB DRI Impact of combined therapy
versus monotherapy
ONTARGET® [33,63] Patients at high risk
of CV events
Ramipril Telmisartan No improvement in CV outcomes;
increased incidence of renal events
due to acute renal failure caused by
concomitant diseases (tumour,
pneumonia, severe diabetes and others)
ALOFT [64] HF Standard therapy Aliskiren Addition of aliskiren to standard treatment
reduced NT-proBNP. Combined therapy
had no effect on UACR
ALLAY [65] Hypertensive patient
with LVH
Losartan Aliskiren No additional benefit over and above
monotherapy
ALTITUDE [66] T2DM patients Standard therapy Aliskiren Increased incidence of AEs in the
combination arm (including non-fatal
stroke, renal dysfunction, hyperkalaemia
and hypotension)
AVOID [12] T2DM patients Losartan Aliskiren Significantly reduced UACR versus losartan
monotherapy
ASPIRE [67] Patients following acute MI Standard therapy Aliskiren Combined therapy did not further
attenuate left-ventricular remodelling
ASTRONAUT [68] Haemodynamically stable,
hospitalizations for heart
failure patients
Standard therapy Aliskiren No reduction in CV death or HF
rehospitalization at 6 months or
12 months after discharge
VA NEPHRON-D [61,69] Patients with diabetes and
overt proteinuria
Lisinopril Losartan Terminated early due to greater number of
observed acute kidney injury events and
hyperkalaemia in the combination group
ACE, angiotensin-converting enzyme; AE, adverse event; ARB, angiotensin II receptor blocker; ALLAY, ALiskiren Left ventricular Assessment of hypertrophY; ALOFT,
ALiskiren Observation of heart Failure Treatment; ALTITUDE, ALiskiren Trial in Type 2 diabetes Using carDio-renal Endpoints; ASPIRE, Aliskiren Study in Post-MI
Patients to Reduce rEmodeling; ASTRONAUT, The AliSkiren TRial ON Acute heart failure oUTcomes; AVOID, Aliskiren in the eValuation of prOteinuria in Diabetes;
CV, cardiovascular; HF, heart failure; LVH, left ventricular hypertrophy; MI, myocardial infarction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide;
ONTARGET®, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial; RAS, renin-angiotensin system; T2DM, Type 2 diabetes mellitus;
UACR, urine albumin-creatinine ratio; VA NEPHRON-D, Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of
Diabetic Nephropathy.
Standard therapy: ALOFT and ASPIRE–ACE inhibitor (or ARB) and β-blocker; ALTITUDE–ACE inhibitor or ARB; ASTRONAUT–included diuretics, ACE inhibitors or
ARBs, β-blockers and aldosterone blocking agents, unless contraindicated.
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(ALOFT) study, patients with stable HF, and treated
with an ACE inhibitor (or ARB) and β-blocker were
randomized to once-daily, double-blind treatment with
aliskiren 150 mg or placebo. After 3 months of treatment,
plasma N-terminal prohormone of brain natriuretic pep-
tide (NT-proBNP) was significantly reduced with aliskiren,
suggesting favourable neurohumoral effects in heart failure
[64]. These beneficial changes in neurohumoral biomarkers
were observed regardless of concomitant mineralocorticoid
treatment received by 33% of patients. The incidence of
pre-specified adverse events (AEs) of renal dysfunction,
symptomatic hypotension and hyperkalaemia was low, and
not significantly different between aliskiren and placebo,
irrespective of whether or not patients were receiving
mineralocorticoid treatment [75].
A meta-analysis of trials comparing ACE inhibitors
alone or in combination with ARBs in patients with LVD
or HF showed an increased risk of developing any AE,
hypotension, worsening renal function and hyperkalaemia
with combination therapy, suggesting ACE inhibitors
should not be routinely used in combination with ARBs inpatients with LVD [76]. A later meta-analysis of trials
comparing ACE inhibitors with ACE inhibitors plus ARBs
in patients with HF showed fewer hospital admissions for
HF with combination therapy (with significant heterogeneity
between included trials), but no difference for overall
mortality, hospitalization for any reason and fatal or
nonfatal MI. Also, patients on combination therapy had a
higher risk of worsening renal function and symptomatic
hypotension, and a higher rate of permanent discontinu-
ation of trial medications [77].
The AliSkiren TRial ON Acute heart failure oUTcomes
(ASTRONAUT) was a double-blind, placebo-controlled
study in which haemodynamically stable hospitalized HF
patients were randomly allocated a median 5 days after
admission to receive 150 mg (increased to 300 mg as
tolerated) of aliskiren or placebo daily, in addition to
standard therapy, which was continued after discharge
for a median 11.3 months. At randomization, patients
(n = 1639) were receiving diuretics (95.9%), β-blockers
(82.5%), ACE inhibitors or ARBs (84.2%), and mineralocor-
ticoid receptor antagonists (57.0%). At 6 and 12 months,
addition of aliskiren to standard therapy did not reduce
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hospitalization. The rates of hyperkalaemia, hypotension
and renal impairment / renal failure were higher in the
aliskiren group compared with placebo [68]. In the CHARM
study, the effects of candesartan in patients with low LVEF
receiving ACE inhibitors (CHARM-Added), and patients
intolerant to ACE inhibitors (CHARM-Alternative), deaths
and hospital admissions for HF were reduced to a greater
extent by candesartan than by standard antihypertensive
treatment [53,54]. However, in patients with preserved LVF,
candesartan did not significantly reduce CV mortality or
hospitalizations for HF [54].
High-risk patients with CKD / Proteinuria
ACE inhibitors and ARBs are widely acknowledged to
confer additional renoprotective benefits beyond the effects
of BP control alone [35] (Table 1). Inhibition of the RAS
slows the progression of renal disease in patients with
diabetes, hypertension and albuminuria, but also decreases
the risk of CV events [15,17,45,78,79]. Few trials have
specifically evaluated the effects of dual RAS inhibition on
mortality in patients with CKD. Instead, most studies have
considered surrogate endpoints [80].
In the ONTARGET® trial, dual RAS inhibition was
associated with a greater risk for the composite out-
come of dialysis, doubling of serum creatinine and death
(compared with ramipril monotherapy) [63], even though
the increase in urine albumin to creatinine ratio (relative
to baseline) was less (p < 0.001). Similarly, a post-hoc
analysis of the ONTARGET® and TRANSCEND® trials that
stratified patients by glomerular filtration rate (GFR) and
albuminuria did not support dual RAS inhibition over
single RAS inhibition in high vascular risk patients with low
GFR or albuminuria [81]. A meta-analysis / metaregression
of trials in patients with primary glomerulonephritis
showed that the antiproteinuric response to ACE inhibitor
plus ARB therapy versus either monotherapy is consistently
greater and strictly related to baseline proteinuria, associ-
ated with only moderate increase in serum potassium
levels and not peculiar to immunoglobulin A nephropathy
[82]. In a retrospective analysis of 6-month data from 16
patients with a single kidney and proteinuria, dual RAS
blockade with several different ACE inhibitors and
ARBs at the maximal dose tolerated by the patient did
not affect plasma creatinine levels or creatinine clearance,
but also did not reduce proteinuria, suggesting lack of
benefit in these patients [83]. In a meta-analysis of 49
randomized trials, which excluded the combination treat-
ment of angiotensin-II receptor blocker and angiotensin-
converting-enzyme inhibitor in non-diabetic renal disease
(COOPERATE) trial (which was retracted due to serious
concerns about the study data), monotherapy with ARBs
and ACE inhibitors was reported to delay progression of
proteinuria over both the short (1–4 months) and longer(5–12 months) term [84]. Although the data were limited,
the combination of the two drugs was considered to reduce
proteinuria more than either drug alone [84].
In a small, randomized cross-over study, 22 patients with
biopsy-proven immunoglobulin A (IgA) nephropathy and
persistent proteinuria despite ACE inhibitor or ARB, were
randomized to either oral aliskiren 300 mg/day or placebo
for 16 weeks and then crossed over to the other treatment
arm after a washout period. After aliskiren treatment, there
was a significant reduction in proteinuria in 4 weeks, which
remained at a low level throughout the treatment period.
There was a significant difference in proteinuria between
the aliskiren and placebo groups from 4 to 16 weeks after
treatment. After aliskiren treatment, there were modest
but statistically significant reductions in estimated GFR
(eGFR) and diastolic BP. None of the patients developed
severe hyperkalaemia (serum potassium ≥ 6.0 mmol/l)
during the study period [85]. In a randomized, open-
controlled, cross-over study performed in 18 whites with
chronic nondiabetic proteinuric kidney disease, after 8 weeks’
combination treatment with telmisartan 80 mg and aliskiren
300 mg (compared with the combination of telmisartan
80 mg and eplerenone 50 mg and telmisartan 160 mg
alone), the urinary excretion of transforming growth fac-
tor β-1 was stable, despite a significant increase in plasma
renin concentration, and there were no differences in
renal function and potassium serum level between the
treatments. There were no episodes of hypotension and
acute renal impairment. Adverse effects were not reported,
suggesting that the combination therapy with telmisartan
and aliskiren may be safe in young nondiabetic patients
with I-II stage CKD at low vascular risk [86]. In a meta-
analysis, combined treatment with an ACE inhibitor plus
ARB was found to be more effective than monotherapy
with an ACE inhibitor / ARB alone for reducing daily
proteinuria in IgA nephropathy, without an increased
risk of hyperkalaemia, but no improvement in GFR was
observed [87].
In a retrospective cohort study of elderly patients in
clinical practice, increased risks of adverse renal outcomes
and hyperkalaemia were observed in those on combin-
ation therapy with an ACE inhibitor and ARB compared
with those on monotherapy [88]. In day-to-day clinical
practice, a multimodal strategy (Remission Clinic) of dual
RAS inhibition with ACE inhibitors and ARBs up-titrated
to maximum tolerated doses, intensified BP control, ameli-
oration of dyslipidaemia by statins, smoking cessation and
healthy lifestyle implementation, was found to safely and
effectively achieve remission or regression of proteinuria
and stabilize kidney function in most CKD patients with
heavy proteinuria despite ACE inhibitor therapy, and almost
fully prevent progression to ESRD [89]. In a community
setting, retrospective cohort-based study, dual therapy
with ACE inhibitor and ARB was associated with
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absolute risks were especially high among patients with
reduced baseline renal function [90].
In an open-label study, 47 patients with advanced CKD
were block randomized to 16 weeks of monotherapy with
increasing doses of RAS blockade aiming at enalapril
20 mg once daily or candesartan 16 mg once daily,
followed by 5 weeks of combination therapy aiming at
combined enalapril 20 mg and candesartan 16 mg for
3 weeks. Twenty-one patients (45%) did not tolerate
dual blockade due to unacceptable plasma creatinine
increase, hypotension, general discomfort or unmanage-
able hyperkalaemia. Hyperkalaemia was reported in seven
(15%) patients [91]. In another open-label study, 67 CKD
patients were randomized to 16 weeks of monotherapy
with either enalapril or candesartan followed by 8 weeks of
dual blockade aiming at a total dose of 16 mg candesartan
and 20 mg enalapril once daily. Dual blockade resulted
in significant BP-independent reductions in aortic pulse
wave volume and in augmentation index compared with
monotherapy. Furthermore, pulse pressure amplification
was improved and central systolic BP was reduced [92].
In a prospective, 12-month study in patients with non-
diabetic proteinuria, with normal or slightly impaired
renal function, combination therapy with ramipril and
valsartan was more efficacious than either monotherapy in
reducing proteinuria and serum creatinine level in the first
3 (proteinuria and serum creatinine) or 6 (serum creatinine)
months of treatment [93].
High-risk patients with diabetes
Diabetes mellitus is considered as a major risk factor for
CVD [94], and CVD is the leading cause of death in
Type 2 diabetes mellitus (T2DM) patients [95]. Guidelines
recommend RAS inhibitors as the first monotherapy for
diabetes patients with hypertension [96,97]. Landmark
trials such as Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation
(ADVANCE) [98], Action to Control Cardiovascular Risk
in Diabetes study [99], ONTARGET® [33] and TRAN-
SCEND® [70] have shown CV and renal benefits with ACE
inhibitors or ARBs in patients with T2DM.
In ONTARGET®, dual RAS inhibition was not found
to be beneficial and was associated with increased harm.
The ALiskiren Trial in Type 2 diabetes Using carDio-renal
Endpoints (ALTITUDE) study evaluated the addition of
aliskiren to an ACE inhibitor or an ARB in T2DM patients
with CKD, CVD or both, but was stopped early due to
safety concerns [66,100]. The study randomized 8,506
patients to aliskiren or placebo added to standard
cardiorenal-protective treatment (an ACE inhibitor or
an ARB). The trial was stopped early because, after the
seventh interim review of data, the Data Monitoring
Committee identified increased incidence of AEs (renaldysfunction, hyperkalaemia, hypotension and an excess of
strokes) in patients in the aliskiren arm and concluded
that patients were unlikely to benefit from aliskiren
treatment added on top of standard antihypertensives
[66]. The Combination Angiotensin Receptor Blocker and
Angiotensin-Converting Enzyme Inhibitor for Treatment
of Diabetic Nephropathy (VA NEPHRON-D) multicentre
trial to assess the effect of the combination of losartan and
lisinopril compared with losartan alone, on the progression
of kidney disease in 1,850 patients with diabetes and overt
proteinuria, was terminated recently for similar reasons to
those of the ALTITUDE study [61,69].
In the Aliskiren in the Evaluation of Proteinuria in
Diabetes (AVOID) study, 599 patients with T2DM, hyper-
tension and nephropathy were randomized to losartan or
losartan plus aliskiren. After 6 months’ treatment, the
dual RAS inhibition treatment was associated with a 20%
reduction in the mean urinary albumin-to-creatinine ratio
compared with single RAS inhibition treatment (p < 0.001).
The mean rate of decline in eGFR was lower with dual
RAS inhibition treatment, but not significantly different
from single RAS inhibition treatment [12]. In a small,
randomized, crossover trial study in 26 patients with
T2DM, hypertension and albuminuria, dual RAS inhibition
with aliskiren plus irbesartan was associated with a signifi-
cantly greater reduction in albuminuria than either of the
single RAS inhibition treatments (dual RAS inhibition, –
71% reduction; aliskiren, –48%; irbesartan, –58%; p < 0.001
versus aliskiren; p = 0.028 versus irbesartan) [101].
In a recent post-hoc subgroup analysis of patients
with diabetes, with or without nephropathy, from the
ONTARGET® trial, it was observed that combination
therapy with telmisartan plus ramipril did not increase the
risk of stroke, other major CV or renal (dialysis or doubling
of serum creatinine) outcomes compared with mono-
therapy, but the AEs of acute dialysis, hyperkalaemia
and hypotension occurred more frequently with combin-
ation therapy [102]. In the Valsartan Aliskiren Hypertension
Diabetes (VIvID) study, 1,143 hypertensive participants
with T2DM and stage 1 or 2 CKD were randomized to
receive combination aliskiren ⁄ valsartan 150 ⁄ 160 mg or
valsartan 160 mg monotherapy for 2 weeks, with force-
titration to 300 ⁄ 320 mg and 320 mg, respectively, for
another 6 weeks. Combination treatment had additive
effects on BP reduction, and tolerability was similar to
valsartan [103].
In an open-label, randomized, parallel-controlled study,
64 hypertensive patients with T2DM and CKD, on
telmisartan 80 mg plus amlodipine 5 mg treatment,
were allocated to receive either aliskiren (150 mg increased
to 300 mg) or an increased dose of amlodipine (10 mg).
After 24 weeks, there was no significant difference between
the two groups in BP decrease, serum creatinine levels
or eGFR rate. However, plasma aldosterone levels were
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with the amlodipine group, and this decrease correlated
significantly with the decrease in urinary 8-hydroxy-2′-
deoxyguanosine and liver-type fatty acid binding protein,
suggesting that the addition of aliskiren to the maximal
recommended dose of ARB and usual dose of amlodipine
is more effective in reducing albuminuria and oxidant
stress in hypertensive diabetic patients with CKD than
increasing the dose of amlodipine [104].
High-risk patients with a broad range of CV risk factors
and TOD
ONTARGET® was one of the largest trials conducted in
over 25,000 patients at high CV risk (defined as those
with coronary, peripheral or cerebrovascular disease, or
diabetes with end-organ damage). The incidence of the
primary endpoint (a composite of CV death, MI, stroke
or hospitalization for HF) was similar in the dual and two
single RAS inhibition groups after a median follow-up of
56 months. However, telmisartan was better tolerated,
even in this population that had been screened for toler-
ance of ACE inhibitors. Compared with ramipril alone,
telmisartan plus ramipril was associated with significantly
higher incidences of hypotensive symptoms (4.8% versus
1.7%; p < 0.001), syncope (0.3% versus 0.2%; p = 0.03) and
renal dysfunction (13.5% versus 10.2%; p < 0.001) [33].
The (AVANT GARDE)-TIMI 43 Trial recruited 1,101
stable patients post acute coronary syndrome having an
increase in natriuretic peptides (NP) without heart failure
or left ventricular dysfunction < 40%. They were random-
ized to 8 weeks’ treatment with aliskiren, valsartan, their
combination or placebo, and there was no evidence for a
benefit of early treatment initiation with valsartan, aliskiren
or their combination compared with placebo [105].
A study in patients with MI, the Aliskiren Study in
Post-MI patients to Reduce rEmodeling (ASPIRE) study,
compared aliskiren with placebo as add on to standard
therapy (an ACE inhibitor or ARB and a β-blocker) [67].
At the end of a 36-week treatment period, no difference
was observed in the primary endpoint of end-systolic
volume change (aliskiren, –4.4 ± 16.8 ml; placebo, –3.5 ±
16.3 ml; p = 0.44). Furthermore, no differences in composite
endpoint of CV death, hospitalization for HF or reduction
in LVEF > 6 points were observed (aliskiren, 7%; placebo,
6%; p = 0.85). Aliskiren added to standard therapy was
associated with more AEs including hypotension, and
increases in creatinine and hyperkalaemia. In 17 patients
with coronary artery disease (CAD) and SBP >130 mmHg
on ACE inhibitor or ARB therapy, addition of aliskiren
150 mg for 6 weeks significantly reduced SBP and plasma
renin activity but did not affect plasminogen activator
inhibitor-1, fibrinogen, or D-dimer levels, suggesting
that dual RAS inhibition does not have any effect on
biomarkers of the fibrinolytic system [106].Discussion
Chronic RAS inhibition using ACE inhibitors or ARBs as
monotherapy is the standard of care to treat the vasocon-
strictive / pro-inflammatory effects of RAS activation.
Despite a strong biological rationale, dual RAS blockade
has been largely disappointing, with initial benefits seen on
surrogate endpoints [55] not being translated to meaning-
ful superior clinical benefit [80]. Data from outcome trials
such as ONTARGET®, VA NEPHRON-D, ALTITUDE and
ASTRONAUT have shown no renal or CV outcome
benefits with dual RAS inhibition, and have even shown
deleterious effects across most patient groups. For ACE
inhibitor / ARB dual therapy, benefits appear confined to
symptomatic HF in patients whose symptoms persist in
the presence of maximized ACE inhibitor and beta-blocker
treatment and not immediately post-MI, and arguably in
severe hypertension while balancing the potential adverse
effects [107].
The ONTARGET® trial was the first to allude to the
need for caution over the use of dual RAS inhibition,
even though the study was not designed to measure the
impact of treatment on renal events [33]. A systematic
review of ARBs and ACE inhibitors in ischaemic heart
disease concluded that dual RAS inhibition with an ARB
and ACE inhibitor is no better than ACE inhibitor or
ARB therapy alone and increases the risk of harm [108].
Dual RAS blockade was not beneficial for clinically relevant
endpoints in patients with diabetic nephropathy [109]. A
systematic review of randomized controlled trials reported
until 2009 also showed lack of evidence to support the use
of combination therapy in people with albuminuria
and one or more CV risk factors [110]. It is of interest
that small studies have shown some benefits in the reduc-
tion of proteinuria with dual RAS blockers in primary
glomerulopathy [82,85].
Dual RAS inhibition studies involving aliskiren also
have not shown consistent benefits but have reported
increased harm with combination treatment. In patients
with uncomplicated Type 1 diabetes, dual RAS blockade
with aliskiren and ramipril was associated with greater
arterial compliance, flow-mediated vasodilatation and
renal vasodilatation [111]. The AVOID and ALTITUDE
studies conducted in patients with diabetes and advanced
CKD did not show beneficial effects of dual RAS inhibition
involving aliskiren, while in the VIvID study conducted in
patients with diabetes and early stages of CKD, the toler-
ability of combination therapy with aliskiren and valsartan
was similar to valsartan monotherapy, although the study
was of a short duration. A meta-analysis that assessed the
combination of aliskiren with other RAS inhibitors reported
an increased risk of hyperkalaemia (but not acute kidney
injury) with combination treatment [112]. A post-hoc
subgroup analysis of ONTARGET® showed no increase in
the risk of stroke, other major CV or renal outcomes in
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unlike the ALTITUDE trial results which suggested that
use of aliskiren in combination with an ACE inhibitor or
an ARB increased risk of stroke in people with diabetes
[100]. However, in both studies, there was an increase in
adverse renal events, suggesting dual RAS inhibition is not
beneficial in these patients [102]. The VA NEPHRON-D
trial was terminated recently for similar reasons to those
of ALTITUDE [69,113]. A recent meta-analysis of 9 studies
with 11,543 patients with diabetes showed that patients
with diabetes receiving dual RAS blockade had a higher
risk (versus monotherapy) of hyperkalaemia, hypotension
and kidney damage, with no reduction in overall mortality.
Except for kidney damage, removing the most influential
study (ALTITUDE) from the analysis did not substantially
alter the results of the analyses [114]. Hence, recent evi-
dence suggests that these combinations should not be
routinely prescribed in patients with diabetes until further
data become available from other future studies [115].
Despite the lack of outcome evidence, dual RAS inhib-
ition was recommended in several guidelines on the basis
of changes in surrogate endpoints such as BP, proteinuria
and endothelial dysfunction [116]. However, the clinical
outcomes and safety data have not confirmed indications
to dual RAS blockade in essential hypertension treatment,
HF and ischaemic heart disease [117]. Existing evidence
indicates that it is reasonable for continued use of ACE
inhibitor plus ARB combination for proteinuric nephropa-
thies and resistant hypertension [117], and for diabetic
nephropathy [107]. Ongoing studies that may give further
insight into the role of dual RAS inhibition are the Long-
term Impact of RAS Inhibition on Cardiorenal Outcomes
(LIRICO), and Aliskiren Trial of Minimizing OutcomeS
for Patients with HEart failure (ATMOSPHERE) compar-
ing aliskiren with aliskiren plus enalapril in patients with
chronic HF. Multi-agent, low-level intervention earlier in
the disease process is yet to be explored [107].
The Canadian Hypertension Education Program has
recommended against use of ARBs and ACE inhibitors
together except in patients with HF refractory to ACE
inhibitor [118]. The American Heart Association guidelines
currently do not recommend the use of ACE inhibitors and
ARBs together, but there is no specific directive warning
against their use in combination. The United States Food
and Drug Administration also has not issued any warnings.
In 2012, the National Healthcare Services professionals
were advised to initiate combination of an ACE inhibitor
and ARB only under specialist supervision in patients with
renal disease, taking into account the potential for adverse
effects such as hyperkalaemia [119]. Based on the ALTI-
TUDE study results, dual aliskiren with ACE inhibitor/ARB
therapy is now contraindicated by the US Food and
Drug Administration in patients with diabetes and is to
be avoided in patients with moderate renal impairment(GFR < 60 ml/min) [120], and is contraindicated by the
European Medicines Agency (EMA) in patients with
diabetes and in patients with moderate renal impairment
(GFR < 60 ml/min) [121].
A recent systematic review and meta-analysis of all
randomized controlled trials reported between January
1990 and August 2012 comparing dual blockers of the
RAS with monotherapy, and reporting data on either
long-term efficacy (≥ 1 year) or safety events (≥ 4 weeks),
and with a sample size of at least 50 (68,405 patients
[mean age 61 years, 71% men] and mean duration of
52 weeks) showed that although dual blockade of the RAS
had seemingly beneficial effects on certain surrogate end-
points, it failed to reduce mortality and was associated
with an excessive risk of AEs such as hyperkalaemia,
hypotension and renal failure compared with monother-
apy. The results of this most comprehensive meta-analysis
to date indicated the risk-benefit ratio argues against the
use of dual therapy [113]. Based on these study results, the
EMA recently started a review of the risks of combining
certain medicines to block separate stages of the RAS
in the treatment of hypertension and congestive heart
failure [122].
Selection of the most appropriate antihypertensive
combination should be dependent on careful review of
the individual patient and appropriate consideration of
drug pharmacology. Existing evidence suggests that in
CV high-risk patients and those with evidence of renal
disease, the use of an ARB plus calcium channel blocker is
the preferred combination due to superior renoprotective
and CV benefits and reduced metabolic side effects in
patients with concomitant metabolic disorders [123].
Conclusions
Although some small studies demonstrate benefits of com-
binations of ARBs with ACE inhibitors, larger clinical trials
such as ONTARGET® and VA NEPHRON-D indicate that
this approach to dual RAS inhibition does not improve
outcomes across most patient groups, and in fact, increases
the risk of AEs. Similarly, dual RAS inhibition involving
aliskiren has been reported in large trials such as ALTI-
TUDE and ASTRONAUT to increase the risk of AEs with
no clinical benefits. A recent meta-analysis of all major
trials involving dual RAS inhibition has clearly shown that
the risk-benefit ratio argues against the use of dual RAS
inhibition. Based on these results, the EMA currently is
reviewing the use of dual RAS blockade in the treatment
of hypertension and congestive heart failure.
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